These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15010881)

  • 1. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
    Yunmbam MK; Guo Y; Miller MR; Yu JJ
    Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
    Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
    Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
    Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
    Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
    Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
    Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
    Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
    Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
    Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
    Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
    Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
    Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
    van de Vaart PJ; van der Vange N; Zoetmulder FA; van Goethem AR; van Tellingen O; ten Bokkel Huinink WW; Beijnen JH; Bartelink H; Begg AC
    Eur J Cancer; 1998 Jan; 34(1):148-54. PubMed ID: 9624250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
    Xiao Y; Lin FT; Lin WC
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33408251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.